← SynDRA
ACLARUBICIN
SynDRA canonical compound SYN0012637 — structure-anchored drug synonym record
| Clinical phase | Launched |
| Primary target(s) | TOP1 | TOP2A |
| Mechanism of action | topoisomerase inhibitor |
| Indication | acute myeloid leukemia (AML) |
| Disease area | hematologic malignancy |
All known targets
- TOP2A
- TOP1
- TOP2B
- HTR2B
- MMP2
Mechanisms of action (all sources)
- topoisomerase inhibitor
- TOP1 INHIBITOR
- TOP2A INHIBITOR
- TOP2B INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ESR1
- ACHE
- MAOA
- NPY2R
- NPY1R
- MMP9
- MMP1
- MC5R
- MC4R
- MC3R
- MAPK3
- MAPK14
- MAPK1
- LCK
- OPRD1
- KCNH2
- HTR6
- HTR2C
- HTR2A
- HTR1A
- HRH3
- HRH2
- HRH1
- HMGCR
- NR3C1
- OPRK1
- FLT1
- SIGMAR1
- TDP1
- TBXAS1
- TBXA2R
- TACR2
- TACR1
- SLCO1B3
- SLCO1B1
- SLC6A4
- SLC6A3
- SLC6A2
- PTPRC
- OPRM1
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- Adjuvants, Immunologic
- Antibiotics, Antineoplastic
- Antineoplastic Agents
- Immunologic Factors
- Enzyme Inhibitors
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
ATC classes
- L01D · CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES
Cross-references
Synonyms
- aclacinomycin
- Aclacinomycin A
- aclacur
- Antibiotic 3082A
- aclarubicin hydrochloride
- aclarubicin HCl
- Aclarubicine
- Aclarubicina
- ACLARUBICIN HYDROCHLORIDE
- Aclacinomycin a
- NSC-208734
- Aclacin
- Aclacur
- Aclarubicino
- Aclarubicinum
- Jaclacin
- Aclucinomycin A
- Antibiotic MA 144A
- Antibiotic MA 144A1
- Antibiotic MA 144G1
- MA 144G1
- Aclarubicine [INN-French]
- Aclarubicino [INN-Spanish]
- Aclarubicinum [INN-Latin]
- Antibiotic MA144-A1
- MA 144-A1
- MA-144A1
- Acene-1-carboxylate
- Aclarubicin (USAN/INN)
- Aclarubicin [USAN:BAN:INN]
- Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester
- 10-epi-Aclacinomycin A
- Aclacinomycin-A
- aclarubicina
- NSC 208734
- CHEBI:74619
- NSC208734
- NSC240619
Look up ACLARUBICIN in the interactive SynDRA portal →